Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) gained almost 4% yesterday in the extended trading hours on insider trading news. One of the major owners, RTW Investments, LP, lapped up 1,355,932 shares of RCKT stock at an average price of $14.75 per share, worth $20 million.
Based in the U.S., Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, focused on the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases.
With the recently reported Buys, the firm now owns 26.69% (17.63 million shares) of the total shares outstanding, with a value of $294.75 million.
Interestingly, TipRanks also provides a list of hot stocks that boasts either a Very Positive or Positive insider confidence signal.
Is Rocket Pharmaceuticals, Inc. (RCKT) a Buy, Sell, or Hold?
The Wall Street community is clearly optimistic about the stock. Overall, the stock commands a Strong Buy consensus rating based on nine unanimous Buys. Rocket Pharmaceuticals stock’s average price target of $57.71 implies a whopping 250.2% upside potential from current levels.
Further, RCKT stock boasts a score of 9 out of 10 on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.
Read full Disclosure
Questions or Comments about the article? Write to editor@tipranks.com